Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:59:56 01/07/2024 BST			5-day change	1st Jan Change
0.0013 ^USD	+4.00%		+18.18%	-89.17%

06-25	Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	CI
06-17	Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	CI

Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024

May 15, 2024 at 09:39 pm

Propanc Biopharma, Inc. reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported net loss was USD 0.5267 million compared to USD 0.809809 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.42 a year ago.
For the nine months, net loss was USD 1.46 million compared to USD 1.91 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 2.08 a year ago.

Latest news about Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	06-25	CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	06-16	CI
Propanc Biopharma, Inc. Enters into and Closed a Loan Agreement with an Investor	06-13	CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	05-30	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-15	CI
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	04-16	CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	04-15	CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	02-29	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-20	CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	01-16	CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	12-10	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	12-03	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding	28/10/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding	19/10/23	CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC	15/10/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC	11/10/23	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	28/09/23	CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding	30/08/23	CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding	29/08/23	CI
Propanc Biopharma, Inc. announced that it has received $0.0725 million in funding from GS Capital Partners LLC	22/08/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.055 million in funding	15/08/23	CI
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	15/08/23	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.12 million in funding	14/08/23	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	14/08/23	CI

Chart Propanc Biopharma, Inc.

Duration

Period

More charts

Company Profile

Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROPANC BIOPHARMA, INC.	-89.17%	229K
VERTEX PHARMACEUTICALS INCORPORATED	+15.82%	121B
REGENERON PHARMACEUTICALS, INC.	+20.35%	113B
ARGENX SE	+17.47%	26.02B
BIONTECH SE	-25.31%	19.39B
GENMAB A/S	-19.51%	15.91B
BEIGENE, LTD.	-19.67%	15.09B
WUXI APPTEC CO., LTD.	-46.87%	15.06B
SAREPTA THERAPEUTICS, INC.	+62.55%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+6.34%	13.85B

Bio Therapeutic Drugs